Home › Research › Biomarkers
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, Stomrud E, Palmqvist S et al.. JAMA neurology, 2021-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To assess how early in the course of AD plasma levels of tau phosphorylated at threonine 217 (P-tau217) start to change compared with levels of established cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers of AD pathology. Main outcomes and measures Changes in plasma P-tau217 levels in preclinical and prodromal AD compared with changes in CSF P-tau217 and PET measures. Results Of 490 participants, 251 were women (51.2%) and the mean (SD) age was 65.9 (13.1) years. When testing the association with global Aβ load in nonlinear spline models, both plasma and CSF P-tau217 were increased at lower Aβ-PET values compared with tau-PET measures.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 225 participants. In 490 people (average age 65.9, 51% women), researchers asked "how early in the course of AD" blood levels of P-tau217 start to change compared with spinal-fluid and PET markers. Reported effect size: 51.2%; 94.7%; 5.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Janelidze, S., Berron, D., Smith, R., Strandberg, O., Proctor, N. K., Dage, J. L., et al. (2021). Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA neurology. https://doi.org/10.1001/jamaneurol.2020.4201
Vancouver
Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA neurology. 2021. doi:10.1001/jamaneurol.2020.4201. PMID: 33165506.
BibTeX
@article{janelidze2021-33165506,
author = {Janelidze, S. and Berron, D. and Smith, R. and Strandberg, O. and Proctor, N. K. and Dage, J. L. and Stomrud, E. and Palmqvist, S. and others},
title = {{Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease}},
journal = {JAMA neurology},
year = {2021},
doi = {10.1001/jamaneurol.2020.4201},
pmid = {33165506},
url = {https://doi.org/10.1001/jamaneurol.2020.4201}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective To assess how early in the course of AD plasma levels of tau phosphorylated at threonine 217 (P-tau217) start to change compared with levels of established cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers of AD pathology.
- Main outcomes and measures Changes in plasma P-tau217 levels in preclinical and prodromal AD compared with changes in CSF P-tau217 and PET measures.
- Results Of 490 participants, 251 were women (51.2%) and the mean (SD) age was 65.9 (13.1) years.
- When testing the association with global Aβ load in nonlinear spline models, both plasma and CSF P-tau217 were increased at lower Aβ-PET values compared with tau-PET measures.
Why it matters
In 490 people (average age 65.9, 51% women), researchers asked "how early in the course of AD" blood levels of P-tau217 start to change compared with spinal-fluid and PET markers. Plotted against the amount of amyloid on PET, "both plasma and CSF P-tau217 were increased at lower Aβ-PET values compared with tau-PET measures", so the fluid marker moved before tau scans did on the amyloid scale. This is an association study of biomarkers for early detection, not a diagnostic accuracy test or a treatment result, and the record we hold gives no numbers for how much earlier.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants225
- Effect size51.2%; 94.7%; 5.3%
- Evidence strengthModerate
How this study scored 75/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 225 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 380 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 54.3 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 5 / 6 | Cited 26.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 41 other studies in this library |
| Still being cited | 4 / 4 | Cited 213 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Lund University: institution h-index 1,119 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33165506) |
| Free to read | 2 / 2 | Free to read |
| Total | 75 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2020.4201
- PubMed: 33165506
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
41 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.